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Background
To verify the importance of provocation tests with
COX2 selective inhibitors before release as an alterna-
tive medication, on patients with a record of cross-
hypersensitivity to non-steroidal anti-inflammatory
(NSAIDs)
Methods
Retrospective analysis of patient records submitted
to provocation tests with COX2 selected inhibitors, in
Policlínica Geral do Rio de Janeiro, in the period
between October 2010 and July 2014. The provocation
tests were simple blind controlled placebo.
Results
One hundred and twenty provocation tests were done
with COX2 selected inhibitors, out of which, 116 with
etoricoxib (96,6%) and 4 with celecoxib (3,3%). One
hundred and two patients were female, with predomi-
nance in ages between 40 and 64 years old (41,8% of the
women). Men represented only 15.9% of patients, with
predominance in ages between 12 and 30 years old
(40,10% of the men). Five positive tests occurred (4,1%),
all of them tested with etoricoxib. In positive cases,
4 patients were female and 1 male, with predominance
in ages between 17 and 29 years old, and 1 patient of
60 years old.
Conclusions
The liberation of alternative medication for patients with
cross-hypersensitivity to NSAIDs should be permitted
only after the realization of provocation tests with
COX2 selective inhibitors, given that 4% of the tests are
positive.
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